Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Prostate Health Index (PHI) can improve the ability to differentiate prostate cancer from noncancerous conditions in prostate disease

Joint Event on 36th World Cancer Conference & 3rd Edition of International Conference on Colorectal Cancer
October 11-13, 2018 Zurich, Switzerland

Josko Osredkar

University Medical Centre Ljubljana, Slovenia

Scientific Tracks Abstracts: Arch Cancer Res

Abstract:

This lecture will address the diagnostic value of free PSA, [-2] pro PSA and PHI in differentiating prostate cancer from benign urological conditions. One of the limiting factors in the clinical application of PSA is the high false positive rate, especially in men with serum PSA levels between 2 to 10 μg/L. Serum PSA levels are elevated in non-cancerous conditions including benign prostate hyperplasia (BPH) and acute prostatitis. Different isoforms of PSA have been discovered, including free PSA (fPSA), proPSA and complexed PSA (cPSA) and these may be able to improve the diagnostic performance of PSA. The prostate health index (PHI) test is a recently approved diagnostic blood test, combining free and total PSA (tPSA) and the pro PSA isoforms ([-2]proPSA) that can reduce the number of negative prostate biopsies in PSA tested men.

Biography :

Professor Osredkar is a head of the research group in Institute of Clinical Chemistry and Biochemistry; he is involved in the projects dealing with biomarkers in cancer disease. He is one of the leaders of subgroup in the national programme “Metabolic and congenital factors of reproductive health, labor”. Within the framework of FP6, he lead Slovenian Research Group in the project Influence of long-term exposure to low concentrations of elements in food in a sensitive population - Public health impact of long-term, low-level mixed element exposure and susceptible population strata (PHIME). His research field today is oxidative stress during pregnancy and the study of oxidative stress in the unborn child, the child immediately after birth to the school period. He seeks to associate oxidative stress during pregnancy with preeclampsia, with Down syndrome and autism.

E-mail: josko.osredkar@kclj.si